Trials / Not Yet Recruiting
Not Yet RecruitingNCT07466550
A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants
A Phase 1 Study in Healthy Subjects to Assess Pharmacokinetics Following Intravenous and Subcutaneous Administration of Risankizumab
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare how the drug moves through the body following risankizumab subcutaneous (SC) and risankizumab intravenous (IV) doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Risankizumab | Intravenous (IV) |
| DRUG | Risankizumab | Subcutaneous (SC) Injections |
Timeline
- Start date
- 2026-03-08
- Primary completion
- 2027-01-01
- Completion
- 2027-01-01
- First posted
- 2026-03-12
- Last updated
- 2026-03-12
Source: ClinicalTrials.gov record NCT07466550. Inclusion in this directory is not an endorsement.